Terumo Cardiovascular Systems Responds to Allegations of Patent Infringement
Terumo Cardiovascular Systems (Terumo CVS)
announced yesterday that it is responding to a patent infringement
complaint by Maquet Cardiovascular LLC. The complaint alleges that Terumo
CVS and its parent company, Terumo Corporation, had infringed on two
patents related to the sale of the Terumo® VirtuoSaph™ Endoscopic Vein
Terumo CVS states that
its policy and its practice are not to infringe on the valid intellectual
property rights of any company. The VirtuoSaph system is protected by
multiple Terumo patents.
"Frankly, we're surprised at this lawsuit as
these patents are several years old and our product has been on the market
for more than three years with great success," says Mark
DiClemente, Vice President, Sales, Terumo Cardiovascular Systems.
"Our competitor has only recently entered the vessel harvesting
market through an acquisition."
Terumo CVS has sold the VirtuoSaph system in the United
States since January 2005. The product is also distributed in Japan and
Asia by Terumo Corporation and in Europe by Terumo's European subsidiary.
The VirtuoSaph system is used during
coronary artery bypass grafting (CABG), the most common cardiac surgery
procedure. During the procedure, the surgeon removes a healthy artery or
vein from elsewhere in the body, most often the saphenous vein in the leg,
and uses it to route blood around a blockage in a coronary artery. The
VirtuoSaph system allows the surgical team to remove the saphenous vein
using very small incisions. Endoscopic procedures have been shown to
minimize scarring, morbidity and infection associated with traditional
Cardiovascular Systems Corporation manufactures and markets medical
devices for the global cardiac surgery markets. The company is
headquartered in Ann Arbor, Michigan with manufacturing operations in Ann
Arbor; Elkton, Maryland; Ashland, Massachusetts; and Tustin, California.
It is one of several subsidiaries of Terumo Corporation of Japan focused
exclusively on the cardiac and vascular markets, including Terumo Heart
Inc., developer of a ventricular assist device. For more information,
Terumo Corporation is a premier global medical device
company with annual sales in excess of ¥270,000 million for the year
ending March 31, 2007. Founded in 1921, the company develops, manufactures
and distributes world-class medical devices for use in cardiothoracic
surgery, interventional procedures, transfusion medicine, and needle and